Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04522622RecruitingPhase 4
Teriparatide for low bone turnover in advanced kidney disease
This trial tests teriparatide (a hormone-like bone medicine) to improve bone health in people with advanced chronic kidney disease who are at risk for weak, low-turnover bone. It may help by changing how quickly your bones break down and rebuild.
AalborgAges 18–120 - NCT04578301Recruiting
Predicting who develops serious liver worsening after surgery
This study looks at your liver health before and after surgery to predict the risk of “acute-on-chronic liver failure,” which means a sudden worsening of liver function on top of an existing liver condition. If you qualify, your doctors may use study data to better identify who needs closer monitoring after surgery.
BonnAges 18 years+ - NCT04588077RecruitingPhase 4
Two-dose vs three-dose hepatitis B vaccine for cirrhosis
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Baltimore, MarylandAges 18 years+ - NCT04613921Recruiting
Liver transplant study for severe worsening liver failure
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
Los Angeles, CaliforniaAges 18–80 - NCT04690972Recruiting
Collection of blood and tissue samples for liver disease research
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
StrasbourgAges 18 years+ - NCT05095714Recruiting
Fast MRI for close monitoring of high-risk liver cancer
This trial studies a faster MRI scan to help track early liver cancer in people who have cirrhosis and are considered high risk. It may improve how often and how well doctors can look for changes without using longer imaging sessions.
BondyAges 18 years+ - NCT05205954Recruiting
Home hospital care for adults with advanced liver disease
This pilot study tests whether a “home hospital” program can safely care for people with advanced liver disease after they are admitted to the hospital. It may reduce time in the hospital while still treating serious complications like fluid buildup, breathing fluid, or confusion from liver disease.
Boston, MassachusettsAges 18 years+ - NCT05335603Recruiting
Study of adults with liver conditions linked to fatty liver
This study looks at adults with different long-term liver conditions that are associated with fatty liver. It helps researchers better understand these diseases and factors linked to them.
HvidovreAges 18 years+ - NCT05475015Recruiting
3D MRI scan to assess liver scarring and pressure
This study tests whether a special 3D MRI scan (3D-MRE) can measure liver scarring and the high pressure in the liver called portal hypertension. It may help your team use imaging to understand how severe your liver disease is, especially when a pressure test (HVPG) is being considered.
Shenyang, LiaoningAges 18–75 - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05727722RecruitingPhase 1
Micro-packaged liver cell transplant for adult liver failure
This Phase 1 study tests a new way to place liver cells (in small protective “micro-packages”) inside the belly to treat liver failure. It aims to see whether the treatment is safe and potentially helps liver function in adults with worsening chronic or acute-on-chronic liver failure.
ShanghaiAges 18–65 - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Chicago, IllinoisAges 18 years+ - NCT05865691Recruiting
Study blood and organ changes in chronic liver disease
This study looks at how blood clotting, inflammation, and blood vessels change in people with chronic liver disease or cirrhosis. Your blood tests may help researchers understand what drives the disease and could guide future care.
ClichyAges 18 years+ - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05998330Recruiting
Palliative care support for advanced liver disease patients
This study tests whether adding palliative care (extra support for symptoms and planning) during a hospital stay helps people with advanced liver disease and their caregivers feel better and plan ahead.
Boston, MassachusettsAges 18 years+ - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT06383208Recruiting
Heart and kidney risk study for people with both diseases
This study looks at how well we can predict heart and kidney problems in people who have both coronary heart disease and chronic kidney disease. By analyzing certain markers, researchers hope to create a better risk assessment tool.
Beijing, Beijing MunicipalityAges 18–80 - NCT06386094Recruiting
Fatty Liver Disease and Heart Function Study
This study checks how fatty liver disease (a condition where fat builds up in the liver) affects the heart. If you have this liver condition and are between 18 and 65, you may help doctors understand the link between liver health and heart function.
Chandigarh, ChandigarhAges 18–65 - NCT06430684RecruitingEarly Phase 1
SGLT2 inhibitor trial for children with kidney disease
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
Chicago, IllinoisAges 12–25 - NCT06432582Recruiting
Liver disease blood marker study for people with stiff livers
This study looks at whether certain micro-RNA levels in your blood can help predict how your chronic liver disease is progressing. It is for people who already have some liver stiffness (measured by a special ultrasound) and are being treated at the University Hospital St. Pölten.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06434753RecruitingPhase 3
Zinc supplements for stable advanced liver disease
This trial tests whether taking zinc supplements can improve the outlook for people with a certain type of advanced liver disease that is still stable (no major complications). If you have compensated advanced chronic liver disease and meet the criteria, you might be able to join.
BarcelonaAges 18–80 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT06523608Recruiting
Predicting liver problems in advanced chronic liver disease
This study looks at people with advanced chronic liver disease to find ways to predict when they might get worse or develop liver cancer. Researchers hope to use this information to prevent complications and improve care.
Münster, North Rhine-WestphaliaAges 18 years+
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 399 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.